Divi's Lab.

Which are the latest news on Divi's Lab.?

Why is Divis Laboratories Ltd falling/rising?

As of 05-Sep, Divis Laboratories Ltd's stock price is falling to 9,100.00, down 1.57% after a trend reversal. Despite this short-term decline, the stock has strong long-term performance, with a year-to-date increase of 42.31% and positive management efficiency.

As of 05-Sep, Divis Laboratories Ltd's stock price is falling, currently at 9,100.00, which represents a decrease of 145.0 or 1.57%. This decline follows a trend reversal after two consecutive days of gains. The stock has underperformed its sector by 1.12% today, indicating a relative weakness in performance compared to its peers.<BR><BR>Despite the current drop, the stock has shown strong performance over longer periods, with a year-to-date increase of 42.31% and a one-year increase of 48.31%. However, the recent weekly performance shows a decline of 1.82%, while the benchmark Sensex has only decreased by 0.97% in the same timeframe. <BR><BR>Additionally, the stock is close to its 52-week high, being just 2.15% away from the peak of Rs 9,296. This proximity to the high may contribute to profit-taking behavior among investors, leading to the current price drop. <BR><BR>On a positive note, the company has demonstrated high management efficiency, is net-debt free, and has reported positive results for the last eight consecutive quarters, which may support its long-term value despite the short-term price decline.

Should I buy, sell or hold Divis Laboratories Ltd?

Who are in the management team of Divi's Lab.?

The management team of Divi's Lab includes key individuals such as Murali K Divi (Chairman & Managing Director), Kiran S Divi (CEO), and several independent directors. They are responsible for guiding the company's strategic direction and operations.

The management team of Divi's Lab includes the following key individuals:<BR><BR>1. **Murali K Divi** - Chairman & Managing Director<BR>2. **N V Ramana** - Executive Director<BR>3. **Madhusudana Rao Divi** - Whole Time Director (Projects)<BR>4. **Kiran S Divi** - Whole Time Director & CEO<BR>5. **Nilima Motaparti** - Whole Time Director - Commercial<BR>6. **G Suresh Kumar** - Independent Director<BR>7. **Ranga Rao Ravipati** - Independent Director<BR>8. **K V K Seshavataram** - Independent Director<BR>9. **Ramesh B V Nimmagadda** - Chairman (Non-Executive) & Independent Director<BR>10. **S Ganapaty** - Independent Director<BR>11. **Sunaina Singh** - Independent Director<BR>12. **Kosaraju Veerayya Chowdary** - Independent Director<BR>13. **Satish Choudhury** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

What does Divi's Lab. do?

Divi's Laboratories Limited is a major pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs) and Nutraceuticals, with a market cap of INR 244,112 Cr. As of June 2026, it reported net sales of 3,080 Cr and a net profit of 902 Cr.

Overview:<BR>Divi's Laboratories Limited is a leading pharmaceutical company engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.<BR><BR>History:<BR>Divi's Laboratories was incorporated in an unspecified year and has established itself as one of the largest API manufacturers globally. The latest quarterly results reported net sales and net profit for the period ending June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 3,080 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 902 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 244,112 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 82.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.32%<BR>- Debt Equity: -0.20<BR>- Return on Equity: 15.65%<BR>- Price to Book: 14.68<BR><BR>Contact Details:<BR>- Address: 1-72-23(P)/DIVIS/303 Divi Tower, Cyber Hills Gachibowli Hyderabad Telangana : 500032<BR>- Tel: 91-40-23786300/23786352/400<BR>- Email: mail@divislabs.com<BR>- Website: http://www.divislaboratories.com

Who are the peers of the Divi's Lab.?

Divi's Lab. peers include Sun Pharma, Torrent Pharma, Zydus Lifesci, Cipla, Laurus Labs, Lupin, Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, and Glenmark Pharma. Notably, Laurus Labs has the highest 1-year return at 122.69%, while Divi's Lab. has a return of 51.10%.

Peers: The peers of Divi's Lab. are Sun Pharma.Inds., Torrent Pharma, Zydus Lifesci., Cipla, Laurus Labs, Lupin, Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, and Glenmark Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Zydus Lifesci., Cipla, Laurus Labs, Lupin, Dr Reddy's Labs, Mankind Pharma, and Glenmark Pharma, while Average management risk is found at Aurobindo Pharma. Growth is excellent at Sun Pharma.Inds., Zydus Lifesci., and Lupin, while below average growth is noted for Divi's Lab., Cipla, Laurus Labs, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, and the rest, while average capital structure is noted for Laurus Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Laurus Labs at 122.69%, while the lowest is Cipla at -10.92%. Divi's Lab.'s 1-year return of 51.10% is significantly higher than Cipla's but lower than Laurus Labs. Additionally, Dr Reddy's Labs and Lupin have negative six-month returns.

How big is Divi's Lab.?

As of 31st August, Divis Laboratories Ltd has a market capitalization of 244,112.00 Cr, with net sales of 11,230.00 Cr and a net profit of 2,925.00 Cr reported in the latest four quarters.

As of 31st August, Divis Laboratories Ltd has a market capitalization of 244,112.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Divis Laboratories reported net sales of 11,230.00 Cr and a net profit of 2,925.00 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with shareholder's funds amounting to 16,761.00 Cr and total assets of 20,019.00 Cr.

Are Divis Laboratories Ltd latest results good or bad?

Divi's Laboratories Ltd reported strong Q1 FY27 results, with net sales of ₹3,080 crores (up 27.80% year-on-year) and a net profit of ₹902 crores (up 65.50% year-on-year), indicating a positive performance and operational efficiency. Overall, the results are considered good for the company.

Divi's Laboratories Ltd has delivered strong results for Q1 FY27, indicating a positive performance overall. The company reported net sales of ₹3,080 crores, which reflects a significant year-on-year growth of 27.80% and an 8.80% increase compared to the previous quarter. This marks the highest quarterly revenue in the company's recent history.<BR><BR>The net profit for the quarter reached ₹902 crores, showing an impressive year-on-year increase of 65.50% and a sequential growth of 20.11%. Operating margins have also expanded dramatically to 40.75%, the highest in eight quarters, demonstrating the company's operational efficiency and pricing power in a competitive market.<BR><BR>Overall, the results indicate that Divi's Laboratories is effectively navigating the post-pandemic landscape and capitalizing on strong demand for its products. The stock has responded positively, with a notable rally in its price following the results announcement. This performance suggests that the latest results are indeed good for the company.

When is the next results date for Divis Laboratories Ltd?

The next results date for Divis Laboratories Ltd is 23 May 2026.

The next results date for Divis Laboratories Ltd is scheduled for 23 May 2026.

Is Divi's Lab. technically bullish or bearish?

As of December 1, 2025, Divi's Lab shows a mildly bullish trend, supported by bullish weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators.

As of 1 December 2025, the technical trend for Divi's Lab has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, the KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates no clear trend on both weekly and monthly charts. Overall, the current technical stance is mildly bullish, driven by the weekly MACD and Bollinger Bands, despite some bearish signals on the monthly indicators.

How has been the historical performance of Divi's Lab.?

Divi's Lab has shown consistent growth in net sales and profitability, with net sales increasing from 4,946.26 Cr in Mar'19 to 9,360.00 Cr in Mar'25, and profit after tax rising to 2,191.00 Cr in Mar'25. The company's total assets also grew significantly, reflecting a strong financial performance overall.

Answer:<BR>The historical performance of Divi's Lab shows a consistent growth trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Divi's Lab has demonstrated a steady increase in net sales, rising from 4,946.26 Cr in Mar'19 to 9,360.00 Cr in Mar'25. The total operating income followed a similar trajectory, reaching 9,360.00 Cr in Mar'25, up from 7,767.00 Cr in Mar'23. Operating profit (PBDIT) also saw fluctuations, peaking at 3,995.81 Cr in Mar'22 before settling at 3,320.00 Cr in Mar'25. Profit before tax increased to 2,916.00 Cr in Mar'25 from 2,163.00 Cr in Mar'24, while profit after tax reached 2,191.00 Cr in Mar'25, up from 1,600.00 Cr in Mar'24. The company's total assets grew significantly from 8,531.32 Cr in Mar'20 to 16,921.00 Cr in Mar'25, reflecting a robust expansion. Total liabilities also increased, but at a slower pace, indicating a strengthening balance sheet. Cash flow from operating activities improved to 1,653.00 Cr in Mar'25, contributing to a net cash inflow of 50.00 Cr for the year. Overall, Divi's Lab has shown resilience and growth in its financial performance across multiple metrics.

Who are the top shareholders of the Divi's Lab.?

The top shareholders of Divi's Lab include promoter Nilima Prasad Divi with 20.34%, foreign institutional investors holding 18.01%, mutual funds at 12.83%, and the Life Insurance Corporation of India as the largest public shareholder with 5.63%. Individual investors own 7.17% of the shares.

The top shareholders of Divi's Lab include the promoters, who hold the majority of the shares. Notably, Nilima Prasad Divi is the promoter with the highest holding at 20.34%. In addition, foreign institutional investors (FIIs) hold 18.01% of the shares, while mutual funds collectively account for 12.83% through 39 schemes. The highest public shareholder is the Life Insurance Corporation of India, which holds 5.63%. Individual investors also have a stake, representing 7.17% of the total shares.

What is the bonus history of the Divi's Lab.?

Divi's Laboratories has a history of issuing bonus shares, with the most recent being a 1:1 bonus announced on September 23, 2015, and a prior 1:1 bonus on August 1, 2009. This reflects the company's consistent practice of rewarding shareholders.

Divi's Laboratories has a history of issuing bonuses. The most recent bonus was a 1:1 bonus issue, which was announced with an ex-date of September 23, 2015, and the record date was September 26, 2015. Prior to that, the company also issued a 1:1 bonus on August 1, 2009, with an ex-date of July 30, 2009. This indicates that Divi's Lab has a consistent practice of rewarding its shareholders through bonus shares.

Has Divi's Lab. declared dividend?

Divis Laboratories Ltd has declared a 1500% dividend, amounting to ₹30 per share, with an ex-date of August 2, 2024. The company has shown strong total returns over various periods, particularly with a 169.61% total return over the past five years.

Divis Laboratories Ltd has declared a 1500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1500%<BR>- Amount per share: 30<BR>- Ex-date: 02 Aug 24<BR><BR>Dividend Yield: 0.45%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.9%, the dividend return was 0%, resulting in a total return of 5.9%.<BR><BR>Over the past year, the price return was 45.73%, the dividend return was 0.67%, leading to a total return of 46.4%.<BR><BR>In the 2-year period, the price return was 84.08%, the dividend return was 1.67%, culminating in a total return of 85.75%.<BR><BR>For the 3-year period, the price return was 85.98%, the dividend return was 2.50%, resulting in a total return of 88.48%.<BR><BR>In the last 4 years, the price return was 52.87%, the dividend return was 2.55%, leading to a total return of 55.42%.<BR><BR>Over the past 5 years, the price return was 164.6%, the dividend return was 5.01%, resulting in a total return of 169.61%.<BR><BR>Overall, Divis Laboratories Ltd has declared a significant dividend, and the total returns over various periods indicate strong performance, particularly in the long term, with substantial price appreciation and increasing dividend contributions.